Business Wire

Perceived burden of disease is greater in younger people living with COPD, global survey reveals

Share

Results of a global survey of 1,375 adults aged at least 45 years old and living with Chronic Obstructive Pulmonary Disease (COPD) in 11 countries have been published in COPD: Journal of Chronic Obstructive Pulmonary Disease.1 Findings indicate that COPD has a substantial physical and psychosocial impact on patients, particularly those aged 45–54 years old. Compared with older patients (≥65 years old), this group more frequently reported that their COPD has a higher impact on their wellbeing and daily activities, and reported making more frequent adjustments to their activity due to their symptoms.1 Survey results indicate that there are significant quality of life and educational unmet needs, particularly amongst younger people living with COPD.

“This is one of the few surveys that looks at the impact of COPD in different age groups,” said Professor Dr Dekhuijzen, Pulmonologist, Radboud University Medical Center, Nijmegen, The Netherlands. “As healthcare professionals, we have to realise that the same disease has a different impact in younger and older patients, and that the perceived impact has to be addressed to tailor and optimise treatment to suit each patient.”

When looking specifically at the outcomes reported by younger patients (45–54 years old) versus older patients (≥65 years old):

  • Younger patients more frequently reported that their COPD ‘extremely’ or ‘very much’ impacts their ability to carry out tasks outside the home (37% vs 22%) and travel long distances (38% vs 18%),1 and they were more than twice as likely to need to plan their day around periods of breathlessness and/or coughing (41% vs 19%)1
  • A significantly higher proportion of patients aged 45–54 years old reported “poor” or “very poor” wellbeing (35% vs 28%; P<0.05), and reported feeling “stressed” and “overwhelmed” 1.7 and 2.2 times more frequently (P<0.05), respectively1
  • Reliance on physicians was more significant amongst younger patients, who were more than three times more likely to want information to aid them to better manage using their inhaler device (18% vs 58% did not want this type of information)1

“One possible explanation as to why the perceived burden differs strongly is that younger patients are usually more active in terms of their work and social life, and so have differing expectations about what life with COPD will be,” said Nicole Hass, Representative from the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA). “Although more research is needed to better understand why these age differences exist, these findings show we need to make patients more aware of how they can positively impact their disease progression through things like speaking to clinicians about optimal treatment aimed at keeping them active in their daily lives.”

Findings reinforce the need for HCPs and COPD patients, particularly younger ones, to work towards optimal treatment management and therapy aimed at improving symptoms and lessening the impact of the disease on patients’ quality of life. According to Dr. Paola Casarosa, Head of Global Therapeutic Areas at Boehringer Ingelheim, “Overall, the results of this survey align with our ongoing efforts as an organisation, highlighting the importance of optimising treatment and helping patients to maintain active lives.”

Intended audiences:
Global and local, in-country medical media.

This press release is issued from our Corporate Headquarters in Ingelheim, Germany, and is intended to provide information about the results of our global COPD patient survey.

For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/perceived-burden-copd-higher-younger-patients

Boehringer Ingelheim

Contact information

Media Contact
Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Kristin Jakobs
55216 Ingelheim/Germany
Phone: +49 6132 77 144553
Mobile: +49 1516 89 47444
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com
www.boehringer-ingelheim.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sagemcom AMI Solution, a Key Driver in the Swedish Energy Transition to a Sustainable Future21.9.2020 10:30:00 CESTPress release

In September, ELLEVIO will continue to improve the Swedish electricity system by being one the first Nordic DSO to start its 2nd generation smart meters large scale rollout. This massive rollout is the result of joint achievements between ELLEVIO, Sagemcom and its local Partner, ONE Nordic. Since the award in March 2019, Sagemcom has developed and delivered a new generation of S211 single phase meters and T211 polyphase meters which allow ELLEVIO to take up the new energy landscape and customer care. The advanced deep indoor dual cellular technology LTE NB IoT + LTE Cat-M is used to secure the reliability of the solution. In less than 8 months and within a specific context, Sagemcom has developed and certified the new generation of smart meters which are installed in the field by ONE Nordic since June 2020 in Stockholm area. The new key features have already been deployed offering a combination of end-user experience - through a customer local interface (P1 Port) - and Low-Voltage netw

Market Failure? kENUP and YUVEDO High-Level Online Event Kick-starts Call for Projects Tackling the Growing Threat of Parkinson’s and Other Neurodegenerative Diseases .21.9.2020 10:14:00 CESTPress release

On Friday, 18 September 2020, YUVEDO Foundation and kENUP Foundation held a high-level online conference to kick-start an open public call for projects tackling the growing threat of Parkinson’s (PD) and other neurodegenerative diseases (NDD). Despite the predictable medical, social and economic challengesof NDDs, too little has happened in recent years to address the underlying causes of NDDs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005283/en/ Market and Regulatory Failure? High-Level Online Conference Kick-starts Open Public Call for Projects Tackling the Growing Threat of Parkinson’s and Other Neurodegenerative Diseases (Photo: Business Wire) An expert report by Professor Maier-Rigaud of NERA Economic Consulting presented at the conference, showed that there are indications for market and regulatory failure around the development of interventions against PD and other NDDs: High risk in product development is

PMI Announces Keynote Speeches at International Forums During UN General Assembly21.9.2020 10:00:00 CESTPress release

MEDIA ADVISORY: Philip Morris International Inc. (PMI) (NYSE: PM) today announced its participation in a series of events over the course of the United Nations General Assembly. Senior executives, including PMI’s CEO André Calantzopoulos and COO Jacek Olczak, will address international forums to talk about the critical role that science can play in driving innovation, progress, and policy to tackle the most pressing global issues. Keynote virtual events include: September 21: PMI COO Jacek Olczak is joining the Diplomatic Courier’s “The SDG’s in Action Forum”discussing “Industry, Infrastructure and Innovation” September 23: Silke Muenster, Chief Diversity Officer, will address The Hill’s “Work Defined” virtual event September 24:PMI CEOAndré Calantzopoulos will present high-level remarks during the 2020 Concordia Annual Summitexploring “Leading Industry Transformation with Purpose” September 29: André Calantzopoulos will be a panelist in a custom event with Dow Jones' The Trust on “Mul

Thales Empowers Organisations to Simplify the Discovery, Protection and Control of Sensitive Data21.9.2020 09:00:00 CESTPress release

Thales today announced the launch of the CipherTrust Data Security Platform, the industry’s first unified data protection solution that enables organisations to discover, protect, and control their most sensitive data wherever it resides. The new platform helps solve key challenges they face today. These include data security complexity caused by multi-cloud adoption, evolving global and regional privacy regulations, as well as the risk of data breaches from external and internal threats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005046/en/ Copyright Thales Drawing from years of data protection innovation, Thales has built the CipherTrust Data Security Platform to seamlessly unify data discovery, classification and data protection, along with strong access controls and centralised key management. The ‘all-in-one’ platform combines the best of Thales’s Vormetric and SafeNet KeySecure technologies to give organisati

Inflazome Announces Acquisition by Roche21.9.2020 08:00:00 CESTPress release

Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones. Inflazome was founded in 2016 by leading medical researchers Prof Matt Cooper (University of Queensland, Australia) and Prof Luke O’Neill (Trinity College Dublin, Ireland). The company is a leader in the development of inflammasome inhibitors. The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need. Matt Cooper, Chief Executive Officer, Inflazome, commented: “We are delighted to close this deal with Roche, an outstanding pharmaceutical company w

Reactev Is Born: a Next-generation Dynamic Pricing Tool21.9.2020 08:00:00 CESTPress release

The digital market is taking competitiveness to new heights. There are greater demands when it comes to decision making and, above all, the speed at which these decisions need to be made. Without a doubt, it’s in pricing strategies that this competitiveness is most palpable. In this context, Reactev was born, the tool that helps retailers make the best pricing decisions at just the right time. This software was developed by Minderest a pioneering company in price, product, and stock monitoring, which has been developing pricing projects for some of the world’s largest companies since 2012. Reactev is a tool created by and for retailers that doesn’t only aim to help them with their processes and decisions, but to also change the way they design their pricing strategies. In a highly competitive environment where, in just seconds, the wrong pricing decision can mean a big loss in sales while the correct decision can strike a blow against the competitions, Reactev equips retailers with its